| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9312209 | Urology | 2005 | 5 Pages |
Abstract
Adjuvant clinical use of pPSA over traditional parameters in selecting treatment strategies for men with PCa cannot yet be definitely determined. However, the promising results in a subgroup analysis warrant further investigation.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
![Additional use of [â2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen-detected prostate cancer](/preview/png/9312209.png "First Page Preview: Additional use of [â2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen-detected prostate cancer")
Authors
Stijn H. de Vries, René Raaijmakers, Bert G. Blijenberg, Stephan D. Mikolajczyk, Harry G. Rittenhouse, F.H. Schröder,